Driving Innovation in Preclinical Metabolic & Cardiovascular Research
Cardiovascular & Metabolic Disease Models
Cardiovascular & Metabolic Disease Models
Medicilon provides a comprehensive portfolio of in vivo models for advancing cardiovascular and metabolic drug development. From obesity, diabetes, and dyslipidemia to hyperuricemia, liver fibrosis, thrombosis, and anemia, our models are designed to closely mimic human pathophysiology, providing translational insights that accelerate therapeutic innovation.
With multi-species capabilities (mice, rats, and hamsters) and fully integrated pharmacology, biomarker discovery, pathology, and PK/PD analysis, our platform enables rapid proof-of-concept through IND-enabling studies.
End-to-End Preclinical Solution
From model induction through IND submission.
Clinically Relevant, High-Throughput Models
Designed for drug efficacy and safety profiling.
Flexible Study Designs
Acute and chronic protocols, customizable for specific mechanisms of action.
Advanced Analytical Capabilities
Biomarkers, histopathology, PK/PD, and imaging included for end-to-end insight generation.
Extensive Cardiovascular & Metabolic Disease Models
Medicilon offers a robust portfolio of in vivo models that mirror human cardiovascular and metabolic diseases—delivering translational insights to speed up drug discovery from obesity to anemia.
Cardiovascular & Metabolic Disease Models
Model Type
Disease Area
Species
- High-fat/high-sugar diet-induced
Mouse/Rat/Hamster
- Streptozotocin (STZ)-induced diabetes
Mouse/Rat
- Spontaneously diabetic (db/db, ob/ob)
Mouse
- ZDF rat model
Rat
- Potassium oxonate-induced
Mouse/Rat
- Adenine/hypoxanthine + potassium oxonate
Rat
- Uric acid/hypoxanthine/yeast-induced
Mouse
- Adenine + ethambutol-induced
Rat
- High-fat diet (HFD) model
Mouse/Rat/Hamster
- MCD diet model
Mouse
- Compound factor-induced
Rat
- TAA-induced hepatic fibrosis
Rat
- ConA/Porcine serum-induced
Mouse/Rat
- Compound factor-induced
Rat
- High-fat/cholesterol/fructose diet
Hamster
- APOE knockout + high-fat diet
APOE Mouse
- Arteriovenous, carotid, tail vein models
Mouse/Rat
- Coagulation time measurement
Mouse
- Renal failure, iron-deficiency, nephrectomy, adenine-induced
Rat
- Middle Cerebral Artery Occlusion
Mouse/Rat
Clinical Relevant Endpoints for Translational Research
Medicilon’s data-driven approach supports cardiovascular and metabolic programs with comprehensive endpoint analysis
These analytical capabilities empower clients to make go/no-go decisions across the discovery and development continuum.
- LC-MS for bioanalytical quantification
- ELISA, immunoassays, and qPCR for biomarker analysis
- Histopathology, IHC, and biochemical profiling
- Cell-based and enzyme activity assays
- Whole-body composition via q-NMR
- Rodent locomotion and energy expenditure via calorimetry
- Custom in vivo, in vitro, and ex vivo solutions tailored to your study goals
Tumor Models
Non-tumor Models
cancer therapy INNOVATION
Beyond Orthotopic Models, A Full-Spectrum Oncology Research Suite
Tumor models:
Medicilon provides a comprehensive range of oncology models, including:
- CDX Models – Fast, reliable tumor models for early-phase drug screening.
- PDX Models – Clinically relevant models for personalized medicine research.
- Syngeneic Mouse Models – Immunocompetent tumor models for evaluating novel cancer therapies in a controlled setting.
- Humanized Mouse Models – Bridge the gap between preclinical and clinical immunotherapy studies.
This holistic approach ensures that researchers can seamlessly transition from early drug discovery to translational research, accelerating the path to clinical trials.
In Vitro Assays for Early Stage Discovery
Complementing our in vivo models, Medicilon offers predictive in vitro systems that bridge bench-to-bedside.
With deep expertise in custom assay development, we work closely with clients to design solutions that align with their mechanism of action, disease biology, and development goals.
- Target Discovery & Validation:
- Using CRISPR, RNAi, and gene editing in human or rodent cell models.
- High-Throughput Phenotypic Assays:
- Including high-content imaging, bioenergetics profiling, and Seahorse analysis.
- Screening Across Modalities:
- Supporting small molecules, biologics, peptides, oligonucleotides, and mRNA therapeutics.
- Biomarker Discovery:
- Employing omics technologies such as metabolomics, lipidomics, and proteomics for translational insights.
